Skin Cancer Detection and Procedural Decisions in Family Practice: When to Biopsy, Use Cryotherapy, or Refer

Introduction: The Primary Care Role in Skin Lesion Evaluation

Family physicians frequently participate in the initial evaluation of skin lesions. Their early decisions can significantly influence whether a potentially malignant lesion is diagnosed promptly or subjected to an inadequate diagnostic procedure.

The most important decision is often not the precise clinical name of the lesion before pathology returns. The immediate question is whether the lesion can reasonably be observed or treated clinically, requires tissue diagnosis, or should be referred because adequate biopsy or definitive treatment exceeds the capabilities of the practice.

This distinction becomes particularly important when cryotherapy is readily available in the office. Liquid nitrogen treatment is fast and evidence based for appropriately selected actinic keratoses. However, destructive treatment does not provide the histopathologic information required to classify an uncertain tumor or assess surgical margins.

Distinguishing Routine Screening from Diagnostic Evaluation

The USPSTF currently assigns an “I” statement to clinician visual skin examination for routine screening of asymptomatic adolescents and adults because available evidence is insufficient to determine the balance of benefits and harms.

This recommendation does not apply to patients who present with suspicious lesions or symptoms such as changes in the size, shape, or color of a skin growth. Once a specific lesion generates concern, the clinical question changes entirely.

A routine examination of an asymptomatic individual represents a screening question. Evaluation of a changing, atypical, bleeding, ulcerated, persistent, or otherwise suspicious lesion represents a diagnostic question. The USPSTF “I” statement on population screening therefore should never be interpreted as a recommendation to defer evaluation of a suspicious lesion.

Recognizing Lesions That May Change Management

Actinic Keratosis: Premalignant Lesions and Field Cancerization

Actinic keratoses are rough, scaly lesions arising primarily on chronically ultraviolet-exposed skin, and they can progress to keratinocyte carcinoma. They are particularly relevant in family practice because many lesions can be treated without referral. The treatment decision depends partly on whether the clinician is sufficiently confident that the lesion is an actinic keratosis rather than an invasive keratinocyte carcinoma or another lesion requiring histopathologic diagnosis.

A single or limited number of typical actinic keratoses can reasonably undergo lesion-directed treatment such as cryosurgery. Multiple lesions or substantial field cancerization may instead favor field-directed treatment because treating only individual visible lesions does not address the broader affected field.

Basal Cell Carcinoma: Risk Stratification and Surgical Cornerstones

BCC should be evaluated according to lesion characteristics and recurrence risk rather than treated as a uniform disease. AAD guidance recommends risk stratification and emphasizes that surgery remains the cornerstone of treatment. Relevant factors include tumor location, size, border definition, recurrent versus primary disease, histologic subtype, and patient characteristics that may affect recurrence or treatment selection.

Low-risk BCC is potentially manageable with standard surgical excision, electrodesiccation and curettage, or topical therapy for appropriate superficial subtypes. Higher-risk lesions and those in cosmetically or functionally sensitive areas warrant consideration of Mohs surgery or another technique providing complete margin assessment. Destructive treatment therefore should not be selected simply because a lesion appears clinically superficial.

Cutaneous Squamous Cell Carcinoma: Identifying High-Risk Features

cSCC also requires careful risk stratification. AAD guidance identifies clinical and pathologic factors that influence recurrence, metastasis, and treatment planning, stating that surgical therapy remains the most effective treatment for most cSCC.

Relevant high-risk characteristics include location and size, poorly defined borders, recurrent disease, immunosuppression, rapid growth, neurologic symptoms, poor differentiation, greater tumor depth, and perineural or vascular involvement. The presence of these features should lower the threshold for specialist treatment rather than encourage increasingly aggressive office-based destructive treatment.

Recognizing and Managing Suspected Melanoma

For pigmented lesions, the ABCDE framework remains a useful component of clinical assessment:

• A: asymmetry
• B: border irregularity
• C: nonuniform color
• D: diameter greater than approximately 6 mm
• E: evolution over time

These characteristics are aids to recognition rather than strict diagnostic requirements. A melanoma does not need to satisfy every ABCDE feature before a biopsy should be considered. Evolution deserves particular attention because clinically meaningful change can identify lesions requiring further evaluation even when other features are less striking.

Clinicians should also avoid assuming that melanoma is confined to patients with light skin. Although melanoma incidence differs by skin pigmentation and racial or ethnic population, the USPSTF notes that patients with darker skin may be diagnosed at later stages and that acral lentiginous melanoma is an important presentation among Black populations.

The Role of Dermoscopy in Primary Care Triage

Dermoscopy can provide additional morphologic information not visible during unaided inspection and may improve triage of suspicious lesions when clinicians have appropriate training.

A systematic review of primary care dermoscopy found that, with appropriate training, dermoscopy was associated with improved diagnostic accuracy and could assist primary care clinicians in deciding between biopsy, referral, or reassurance. The studies were heterogeneous, however, and relatively few were conducted entirely within routine primary care settings. Minimum training requirements also remain uncertain.

A more recent meta-analysis demonstrated substantial differences in diagnostic performance according to physician specialty, experience, lesion type, and examination method. Dermoscopy can therefore extend primary care examination skills, but it should not substitute for histopathology or specialist evaluation when meaningful diagnostic uncertainty remains.

Determining When to Biopsy and How to Preserve Tissue

Preserving Tissue When Histology Dictates Management

A destructive procedure is poorly suited to an uncertain lesion when subsequent management depends on histopathologic diagnosis. This is particularly important when the differential diagnosis includes melanoma, invasive cSCC, or a higher-risk BCC.

A practical rule follows: when knowing what the lesion is will change treatment, obtain adequate tissue rather than destroying the lesion without histology.

Biopsy Techniques for Suspected Melanoma

The preferred diagnostic procedure for a lesion suspicious for melanoma is a narrow excisional or complete biopsy that encompasses the entire breadth of the lesion with approximately 1 to 3 mm clinical margins and sufficient depth to avoid transection at the base.

Complete biopsy can be accomplished by more than one technique. Depending on lesion characteristics, acceptable methods can include elliptical excision, punch excision when the entire lesion can be encompassed, or sufficiently deep shave or saucerization. Deep shave or saucerization should not be confused with a superficial shave biopsy. Complete deep saucerization extending sufficiently below the anticipated plane of the lesion may permit assessment of Breslow thickness. Superficial sampling that transects an invasive melanoma can severely compromise microstaging.

The purpose of the initial biopsy is diagnostic and microstaging accuracy rather than immediate definitive wide excision. If complete biopsy is impractical because of lesion size, facial or acral location, anatomy, or other clinical circumstances, partial sampling may sometimes be necessary. When the clinician cannot obtain an appropriate specimen, referral is always preferable to an inadequate procedure.

Biopsy Approaches for Suspected Keratinocyte Carcinomas

No single biopsy technique is preferred for every suspected keratinocyte carcinoma. For lesions suspected of being BCC or cSCC, shave, punch, incisional, or excisional biopsy may be selected according to lesion characteristics, patient factors, and clinical judgment.

The objective is to obtain sufficient tissue to establish the diagnosis and provide the pathologist with information needed to identify features that may alter management. A superficial sample may be inadequate when clinically important invasive or aggressive features lie deeper in the lesion. Biopsy depth should therefore reflect the diagnostic question rather than simply the easiest technique available.

Managing Clinicopathologic Discordance

Pathology must always be interpreted in the context of the lesion that was sampled. Current family medicine literature specifically recommends prompt dermatology referral when clinical suspicion remains substantial despite apparently benign histology.

Discordance can occur when an unrepresentative portion of a heterogeneous lesion is sampled or when the biopsy fails to capture the clinically concerning component. A benign pathology report therefore should not automatically terminate evaluation when the clinical appearance or behavior of the lesion remains concerning. Appropriate next steps may include clinical-pathologic correlation, repeat biopsy, or specialist evaluation.

Table 1. Primary Care Biopsy Decision Framework

Clinical situation	Preferred pathway	Key principle
Typical isolated actinic keratosis with adequate diagnostic confidence	Cryosurgery is an evidence-supported option.	Histology is not required for every clinically typical actinic keratosis.
Lesion suspicious for BCC or cSCC	Obtain an appropriate shave, punch, incisional, or excisional biopsy.	Provide adequate tissue for diagnosis and risk assessment.
Lesion suspicious for melanoma	Narrow complete biopsy with approximately 1 to 3 mm margins and adequate depth when feasible.	Preserve accurate microstaging, including assessment of Breslow thickness.
Melanoma-suspicious lesion that cannot be adequately sampled in the office	Prompt referral.	Do not substitute an inadequate or destructive procedure.
Benign pathology but persistent clinical concern	Reassess, repeat appropriate sampling, or refer.	Resolve clinicopathologic discordance.

Appropriate Indications and Limitations for Cryotherapy

Cryotherapy for Actinic Keratosis

Actinic keratosis is the clearest evidence-based indication for cryosurgery within the scope of this article. The AAD guideline gives a strong recommendation for cryosurgery in patients with actinic keratoses. Cryosurgery is particularly appropriate for a single lesion or limited number of discrete lesions. When numerous lesions or substantial field cancerization are present, field-directed therapies may provide a more appropriate strategy than treating each visible lesion individually.

Red Flags for Reconsidering Cryotherapy

Cryotherapy should never substitute for diagnostic certainty. If a lesion thought to be an actinic keratosis has features that raise concern for invasive or alternative malignancy, the diagnosis should be reconsidered before repeated destruction.

Likewise, a lesion that persists, recurs, enlarges, or otherwise behaves unexpectedly after treatment warrants reassessment rather than automatic repeat cryotherapy. When the differential diagnosis includes a malignancy for which histologic subtype, invasion, depth, or other pathologic characteristics will influence management, biopsy or referral is the safer pathway.

Why Cryotherapy Is Not Routine for Basal Cell Carcinoma

For family practice decision-making, cryotherapy should not be presented as a routine treatment pathway for BCC. AAD guidance emphasizes that surgery remains the cornerstone of BCC treatment and that nonsurgical treatments have lower cure rates than surgery. They are generally reserved for selected low-risk tumors or situations in which surgery is contraindicated.

Standard excision and electrodesiccation and curettage are among the options for low-risk BCC, with topical agents applicable to selected superficial subtypes. High-risk BCC and lesions in cosmetically or functionally sensitive locations warrant Mohs surgery or a comparable strategy providing complete margin assessment. A lesion suspected to be BCC should therefore generally undergo diagnostic confirmation and risk assessment before definitive treatment is selected.

The Restricted Role of Cryotherapy in Squamous Cell Carcinoma

Cryosurgery has a more explicitly defined but still restricted role in cSCC. AAD guidance states that surgical therapy is generally the most effective treatment. Nonsurgical therapies, including cryosurgery, may be selected for low-risk tumors or when surgery is contraindicated, with recognition that cure rates may be lower.

The full AAD guideline further limits cryosurgery to situations involving low-risk cSCC when more effective therapies are contraindicated or impractical. This role differs substantially from cryosurgery in actinic keratosis. Routine cryotherapy should therefore not be the default management of invasive cSCC in family practice. High-risk disease, recurrent disease, significant immunosuppression, aggressive histology, perineural involvement, or anatomically challenging disease should favor a specialist-directed pathway.

The Absolute Contraindication of Cryotherapy for Suspected Melanoma

Cryotherapy has no role in the diagnostic management of a lesion suspicious for invasive melanoma. Melanoma treatment planning depends entirely on histopathologic diagnosis and microstaging. A destructive procedure performed before appropriate tissue sampling can eliminate the ability to obtain information required for accurate subsequent management. The appropriate pathway is biopsy using an oncologically appropriate technique or referral when such a biopsy cannot be performed adequately.

Table 2. Practical Role of Cryotherapy

Lesion	Role of cryotherapy	Primary care implication
Typical isolated actinic keratosis	Established treatment with a strong AAD recommendation.	Appropriate when diagnostic confidence is adequate.
Multiple actinic keratoses or field cancerization	Individual cryotherapy may be less suitable than field-directed treatment.	Match therapy to the extent of disease.
Suspected BCC	Not a routine diagnostic or default treatment pathway in this framework.	Establish diagnosis and risk before selecting treatment.
Confirmed low-risk cSCC	Restricted option when more effective treatment is contraindicated or impractical.	Surgery remains preferred in most cases.
Suspected melanoma	No role as a diagnostic procedure.	Perform an appropriate biopsy or refer.

Knowing When to Refer to Dermatology or Surgical Oncology

Referral is an integral part of safe primary care skin cancer management rather than evidence of procedural failure. The referral threshold should reflect whether the clinician can obtain adequate diagnostic tissue and whether definitive treatment can be performed without compromising oncologic or functional outcomes.

1. When an Appropriate Melanoma Biopsy Is Not Feasible in Office

A melanoma-suspicious lesion should be referred when its location, size, anatomy, or other circumstances make an adequate complete biopsy impractical in the primary care setting. An intentionally superficial procedure should not be substituted simply because it is easier to perform.

2. When Clinical Suspicion Persists Despite Benign Histology

Persistent clinicopathologic discordance is a specific reason for dermatology referral. The clinical question has not been resolved merely because an initial specimen was interpreted as benign.

3. Managing Higher-Risk or Anatomically Sensitive Basal Cell Carcinomas

Higher-risk BCC and tumors involving cosmetically or functionally sensitive locations may require Mohs surgery or another method providing comprehensive margin assessment. Features influencing risk classification include recurrence, aggressive histologic subtype, poorly defined clinical borders, and high-risk anatomic location.

4. Addressing Invasive or High-Risk Squamous Cell Carcinomas

Invasive cSCC should generally be approached surgically. Referral is particularly appropriate when risk factors include recurrent disease, immunosuppression, poorly defined borders, rapid growth, neurologic symptoms, aggressive or poorly differentiated histology, greater depth, or perineural involvement.

5. When Anatomy Demands Specialized Tissue Preservation

Lesions on cosmetically or functionally sensitive sites may require procedures that maximize tissue conservation while providing reliable margin assessment. In these settings, performing a readily available office procedure is not necessarily equivalent to providing the most appropriate oncologic treatment.

6. When Diagnostic or Procedural Confidence Is Insufficient

Dermoscopy can improve lesion assessment when clinicians are trained, but diagnostic performance varies substantially according to expertise. Referral should remain readily available when the clinician cannot confidently determine whether observation, biopsy, or treatment is appropriate.

Special Clinical Considerations for Vulnerable Populations

Evaluating Skin Cancer in Patients With Darker Skin Tones

Population-level differences in melanoma incidence must not create false diagnostic reassurance. The USPSTF notes that melanoma is substantially less common in Black than White populations but that persons with darker skin may be diagnosed at later stages.

Acral lentiginous melanoma, which commonly involves palms, soles, or subungual sites, is an important melanoma presentation among Black populations. Suspicious lesions in these locations deserve the exact same diagnostic attention as lesions on more conventionally sun-exposed sites.

Navigating Immunosuppression and Elevated Malignancy Risk

Immunosuppression is an important component of cSCC risk stratification. A suspected or confirmed cSCC in an immunosuppressed patient therefore warrants a lower threshold for specialist involvement than an otherwise comparable low-risk lesion in an immunocompetent patient. The decision should be based on the complete tumor and patient risk profile rather than immunosuppression in isolation.

A Step-by-Step Decision Pathway for Family Practice

Step 1: Determine Whether This Is Screening or Diagnosis An asymptomatic patient without an identified concerning lesion falls within the population addressed by the USPSTF screening recommendation. Evidence remains insufficient to determine the balance of benefits and harms of routine clinician visual screening. A patient presenting with a changing or suspicious lesion is outside that screening population and requires diagnostic evaluation.

Step 2: Decide Whether the Lesion Is a Typical Actinic Keratosis If the lesion is a clinically typical isolated actinic keratosis and diagnostic confidence is adequate, cryosurgery is an evidence-supported treatment. If the lesion is atypical, behaves unexpectedly, or raises concern for invasive disease, reconsider the diagnosis before destruction.

Step 3: Ask Whether Melanoma Is Plausible If melanoma is reasonably suspected, obtain a complete narrow biopsy with approximately 1 to 3 mm margins and adequate depth when feasible. Deep shave or saucerization can be appropriate when performed deeply enough to accomplish a complete biopsy. If an adequate biopsy cannot be performed, refer.

Step 4: Ask Whether BCC or cSCC Is Plausible Obtain adequate diagnostic tissue using a shave, punch, incisional, or excisional technique selected according to lesion characteristics and the clinical question. Then use the pathology, location, tumor characteristics, and patient factors to determine whether treatment in primary care remains appropriate.

Step 5: Identify High-Risk Features High-risk location, recurrent disease, aggressive histologic subtype, poorly defined borders, immunosuppression, significant invasion, perineural involvement, or other adverse features should shift management toward specialist care.

Step 6: Compare Pathology With the Clinical Lesion If the pathology result does not adequately explain a clinically concerning lesion, do not automatically close the diagnostic process. Reassessment, repeat sampling, dermatopathologic correlation, or dermatology referral may be needed.

Core Clinical Implications for Primary Care Practice

The distinction among biopsy, cryotherapy, and referral is fundamentally a question of diagnostic certainty.

Cryosurgery is useful precisely because a typical actinic keratosis often does not require tissue confirmation before treatment. That logic does not extend to an uncertain pigmented lesion, suspected invasive keratinocyte carcinoma, or tumor whose histologic characteristics determine subsequent treatment.

The same principle applies to biopsy technique. Obtaining tissue is not sufficient if the specimen cannot answer the clinically important question. A melanoma-suspicious lesion requires a specimen capable of supporting accurate diagnosis and microstaging.

Dermoscopy can improve lesion triage, particularly when clinicians have appropriate training, but its value lies in augmenting clinical judgment rather than eliminating the need for pathology or specialist expertise.

Acknowledging the Limitations of Current Evidence

The USPSTF continues to find insufficient evidence to determine whether routine clinician visual skin examination of asymptomatic adolescents and adults improves net health outcomes. This uncertainty applies to population screening rather than evaluation of an identified suspicious lesion.

Evidence on dermoscopy in primary care is heterogeneous. Training methods, clinician experience, lesion populations, diagnostic thresholds, and study settings vary substantially.

The evidence base for cryosurgery in established cSCC is considerably weaker than the evidence supporting cryosurgery for actinic keratosis, which is reflected in the more restrictive cSCC recommendation.

Risk-stratification criteria for BCC and cSCC can evolve as specialty guidance changes. Clinicians using detailed treatment algorithms should ensure that the risk criteria applied in practice reflect the current specialty guideline rather than relying indefinitely on older classifications.

Future Directions and Emerging Diagnostic Technologies

Improved access to dermoscopy, structured training, teledermatology, and validated image-based decision-support systems may significantly improve primary care triage of suspicious skin lesions in the coming years.

Current evidence does not support replacing histopathologic diagnosis or specialist evaluation with image analysis alone. The most clinically useful role for emerging tools is likely to be augmentation. These technologies will ideally help clinicians decide which lesions require biopsy, which patients need expedited referral, and which apparently benign or premalignant lesions can reasonably remain within the primary care setting.

Conclusion: Prioritizing Diagnostic Certainty Over Procedural Convenience

Skin cancer procedural decisions in family practice should follow a simple principle: preserve diagnostic information whenever the diagnosis could alter treatment.

A clinically typical isolated actinic keratosis can often be treated directly with cryosurgery, an approach strongly recommended by the AAD. A lesion suspicious for BCC or cSCC generally requires adequate diagnostic assessment before definitive treatment, followed by risk-based selection of therapy. A lesion suspicious for melanoma requires an appropriately planned biopsy that preserves the histopathologic information necessary for diagnosis and microstaging.

Cryotherapy should therefore be viewed primarily as a treatment for appropriately selected premalignant lesions within this primary care framework, not as a diagnostic shortcut for an uncertain tumor.

Referral should be prompt when an adequate biopsy cannot be performed, when pathology and clinical findings remain discordant, when higher-risk tumor characteristics are present, or when definitive treatment requires specialist expertise or comprehensive margin control.

References

1. U.S. Preventive Services Task Force. (2023). Skin Cancer: Screening. Final Recommendation Statement. April 18, 2023. Accessed August 7, 2026. https://www.uspreventiveservicestaskforce.org/uspstf/
   document/RecommendationStatementFinal/skin-cancer-screening
2. Nelson M, Hamel RK, Nash J. (2026). Skin Cancer: Diagnosis. FP Essentials. 564:14-22. PMID: 42166763. https://pubmed.ncbi.nlm.nih.gov/42166763/
3. Swetter SM, Tsao H, Bichakjian CK, et al. (2019). Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology. 80(1):208-250. doi:10.1016/j.jaad.2018.08.055. PMID: 30392755. https://pubmed.ncbi.nlm.nih.gov/30392755/
4. Eisen DB, Asgari MM, Bennett DD, et al. (2021). Guidelines of care for the management of actinic keratosis. Journal of the American Academy of Dermatology. 85(4):e209-e233. doi:10.1016/j.jaad.2021.02.082. PMID: 33820677. PMCID: PMC12255292. https://pubmed.ncbi.nlm.nih.gov/33820677/
5. Nelson M, Nash J, Hamel RK. (2026). Skin Cancer: Management of Actinic Keratoses and Keratinocyte Carcinomas. FP Essentials. 564:23-32. PMID: 42166764. https://pubmed.ncbi.nlm.nih.gov/42166764/
6. Kim JYS, Kozlow JH, Mittal B, et al. (2018). Guidelines of care for the management of basal cell carcinoma. Journal of the American Academy of Dermatology. 78(3):540-559. doi:10.1016/j.jaad.2017.10.006. PMID: 29331385. https://pubmed.ncbi.nlm.nih.gov/29331385/
7. Kim JYS, Kozlow JH, Mittal B, et al. (2018). Guidelines of care for the management of cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology. 78(3):560-578. doi:10.1016/j.jaad.2017.10.007. PMID: 29331386. PMCID: PMC6652228. https://pubmed.ncbi.nlm.nih.gov/29331386/
8. Jones OT, Jurascheck LC, van Melle MA, et al. (2019). Dermoscopy for melanoma detection and triage in primary care: a systematic review. BMJ Open. 9(8):e027529. doi:10.1136/bmjopen-2018-027529. PMID: 31434767. PMCID: PMC6707687. https://pubmed.ncbi.nlm.nih.gov/31434767/
9. Chen JY, Fernandez K, Fadadu RP, et al. (2025). Skin Cancer Diagnosis by Lesion, Physician, and Examination Type: A Systematic Review and Meta-Analysis. JAMA Dermatology. 161(2):135-146. doi:10.1001/jamadermatol.2024.4382. PMID: 39535756. PMCID: PMC11561728. https://pubmed.ncbi.nlm.nih.gov/39535756/